Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

Determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (immune checkpoint inhibitors) in adult patients with metastatic NSCLC with liver metastases.

Trial Details

NCT ID
NCT05430009
Phase
PHASE1
Sponsor
VA Ann Arbor Healthcare System
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Liver SBRT
  • Pembrolizumab
Locations (sample)
  • Ann Arbor, Michigan, United States|42.27756,-83.74088

Key Eligibility Criteria

  • Adult patients (≥18 years of age)
  • Histologically or cytologically confirmed NSCLC with liver metastases
  • Eligible for immune checkpoint inhibitors per treating medical oncologist
  • Disease must be measurable per RECIST criteria

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →